PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests

PAVmed Inc.

2026-Q1 EPS reported -$4.42 revenue$22,000

GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).
Cash and equivalents $6.5M at Mar 31, up from $1.5M at Dec 31, 2025.
Lucid Diagnostics Q1 EsoGuard revenue $1.3M, 3,177 tests processed; raised $17M in public offering, proforma cash $45M.
Veris Health advancing implantable physiological monitor towards FDA 510(k) submission.
PAVmed relaunched medical device portfolio including PortIO and Duke-licensed endoscopic imaging.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PAVmed Inc. reported first quarter ended March 31, 2026 results: net income approximately $7.0 million, EPS $(4.42) per common share on a diluted basis.

Period: first quarter ended March 31, 2026
Net income: approximately $7.0 million
EPS: $(4.42) per common share on a diluted basis
Result: reported results

Exact text from the filing

On May 15, 2026, PAVmed Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.